Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598296 | 0.99 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNAHTTCASP3 | |
| Bromide SCHEMBL1194391 | 0.92 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL3689760 | 0.92 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| Bromide SCHEMBL6598138 | 0.79 | MAPT (0.32) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL6597394 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| Bromide SCHEMBL1194586 | 0.76 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL6618821 | 0.75 | MAPT (0.36) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL6596219 | 0.74 | MAPT (0.35) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| Hydrochloric Acid SCHEMBL1193715 | 0.74 | MAPT (0.34) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| Bromide SCHEMBL6597813 | 0.72 | MAPT (0.34) | ALDH1A1LMNAHTTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | claimed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | claimed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | SMN1; SMN2 4239/4885ALDH1A1 132/4885LMNA 641/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | SMN1; SMN2 4474/4885ALDH1A1 226/4885LMNA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.